Paxlovid

Researchers found the antiviral treatment was disproportionately given to patients with lower risk of severe infection and, if properly utilized, more than 16,000 COVID deaths could have been prevented.

The drug has been fully vetted by the U.S. government and can remain on the market indefinitely. Millions of Americans have received Paxlovid since it was granted emergency authorization in 2021.

The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021. The FDA has the final say on giving Pfizer's drug full approval and is expected to decide by May.

COVID-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.

The drug is the most effective way to cut the risk of severe disease. It's heading to China now. Yet the drug is underused in some places. Why? And are there options if you're not a good candidate?

The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.

The treatments were highly popular earlier in the pandemic. One by one, they got knocked out by more convenient, less expensive treatment options, and new COVID variants.

For those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.

The White House announced the initiative this week as part of President Joe Biden’s push to increase COVID vaccinations and treatments to slow a possible fall and winter surge.

Paxlovid has been highly effective at reducing the risks of hospitalization and death, but some patients report a "Paxlovid rebound," in which the disease returns.